Mazzucchelli I, Decembrino L, Garofoli F, Ruffinazzi G, Ramoni V, Romano M, Prisco E, Locatelli E, et al
Journal of Epidemiology & Community Health , 79(4), 257-264
G-protein-based GLP-1 agonists appear to achieve significant weight and blood sugar-reducing effects, in part through reduced beta-arrestin recruitment, thereby avoiding receptor desensitization and downregulation [25]
Promotes healthy mitochondrial function
In some cases, individuals allege that symptoms persisted even after discontinuing the medication, requiring additional medical treatment or hospitalization
To be eligible, participants had to be between 25 and 40 years of age, to be healthy as per site physician medical assessment, to be working for 812 h per day, and to have a body mass index (BMI) between 18.5 and 27.5 kg/m 2